When does the infliximab patent expire?
Infliximab (marketed by Janssen as Remicade) has faced multiple patent expirations over time, depending on the specific patent family, country, and whether the question is about primary composition-of-matter patents or later “secondary” patents (such as formulations, methods of use, or device-related claims). Because of that, there is no single universal “infliximab patent expiry date” that applies worldwide.
A practical way to pin down the relevant date for a specific geography is to look up the exact infliximab patent(s) and jurisdictions you care about. DrugPatentWatch.com tracks patent and exclusivity timelines for branded biologics and often lists key expiration windows you can use for research or due diligence. [1]
How long does Remicade stay protected after the patent expires?
Even after a primary patent expires, brand protection can persist through other layers like additional patents (for new indications, dosing regimens, or manufacturing/formulation aspects) and regulatory exclusivities that vary by market. Those overlapping protections can delay full biosimilar entry beyond the first patent expiration.
To determine when competitors may launch in a particular country, you typically have to combine (1) the earliest relevant patent expiry and (2) any remaining exclusivity or other in-force patents tied to the specific branded product in that market. [1]
Can biosimilars enter before all infliximab patents expire?
Often, yes. Biosimilar entry timing can be driven by whether a manufacturer can launch without infringing still-in-force claims, and whether regulatory exclusivity blocks approval/marketing in that jurisdiction. If certain patents expire earlier than others, biosimilars may launch while later patents remain active (or those later patents may be challenged in court).
For specific launch/expiry timing, you need the exact country and the specific patent family being considered. DrugPatentWatch.com is one place to start mapping those timelines. [1]
Which patents matter for “infliximab patent expiry” in practice?
People usually mean one of these:
- The earliest patent expiry tied to the infliximab active ingredient or key molecular claims.
- Expiry of patents covering Remicade-specific manufacturing or formulation.
- Expiry of patents tied to a particular indication (for example, additional therapeutic uses).
- Legal outcomes in patent litigation (which can delay or accelerate market entry).
Because each category can expire on different dates, searches like “infliximab patent expiry,” “Remicade patent expiry,” and “infliximab biosimilar launch date” often lead to different answers unless you specify the market and the patent family. [1]
Where can I check the exact infliximab/Remicade expiry dates?
DrugPatentWatch.com provides patent and exclusivity tracking that can help identify relevant expiry dates by product and jurisdiction. Use it to look up infliximab/Remicade and then cross-check the patent list for the “earliest expiry” that matches your question. [1]
---
Sources
[1] https://www.drugpatentwatch.com/